Next Article in Journal
Effect of Surfactant Type and Sonication Energy on the Electrical Conductivity Properties of Nanocellulose-CNT Nanocomposite Films
Next Article in Special Issue
Effect of Inhibition of DNA Methylation Combined with Task-Specific Training on Chronic Stroke Recovery
Previous Article in Journal
Studies of Microbiota Dynamics Reveals Association of “Candidatus Liberibacter Asiaticus” Infection with Citrus (Citrus sinensis) Decline in South of Iran
Previous Article in Special Issue
Effects of Protocatechuic Acid (PCA) on Global Cerebral Ischemia-Induced Hippocampal Neuronal Death
Open AccessReview

Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy

1
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
2
Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan
3
Department of Chemistry, North Eastern Hill University, Shillong 793022, India
4
Department of Evolution, Ecology and Organismal Biology, Ohio State University, Columbus, OH 43212, USA
5
Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
*
Author to whom correspondence should be addressed.
These two authors contributed equally to this work.
Int. J. Mol. Sci. 2018, 19(6), 1818; https://doi.org/10.3390/ijms19061818
Received: 1 June 2018 / Revised: 13 June 2018 / Accepted: 15 June 2018 / Published: 20 June 2018
(This article belongs to the Special Issue Molecular Pharmacology and Pathology of Strokes)
In oncotherapy, ruthenium (Ru) complexes are reflected as potential alternatives for platinum compounds and have been proved as encouraging anticancer drugs with high efficacy and low side effects. Cardiovascular diseases (CVDs) are mutually considered as the number one killer globally, and thrombosis is liable for the majority of CVD-related deaths. Platelets, an anuclear and small circulating blood cell, play key roles in hemostasis by inhibiting unnecessary blood loss of vascular damage by making blood clot. Platelet activation also plays a role in cancer metastasis and progression. Nevertheless, abnormal activation of platelets results in thrombosis under pathological settings such as the rupture of atherosclerotic plaques. Thrombosis diminishes the blood supply to the heart and brain resulting in heart attacks and strokes, respectively. While currently used anti-platelet drugs such as aspirin and clopidogrel demonstrate efficacy in many patients, they exert undesirable side effects. Therefore, the development of effective therapeutic strategies for the prevention and treatment of thrombotic diseases is a demanding priority. Recently, precious metal drugs have conquered the subject of metal-based drugs, and several investigators have motivated their attention on the synthesis of various ruthenium (Ru) complexes due to their prospective therapeutic values. Similarly, our recent studies established that novel ruthenium-based compounds suppressed platelet aggregation via inhibiting several signaling cascades. Our study also described the structure antiplatelet-activity relationship (SAR) of three newly synthesized ruthenium-based compounds. This review summarizes the antiplatelet activity of newly synthesized ruthenium-based compounds with their potential molecular mechanisms. View Full-Text
Keywords: ruthenium complex; antiplatelet; antithrombosis; signaling cascades ruthenium complex; antiplatelet; antithrombosis; signaling cascades
Show Figures

Figure 1

MDPI and ACS Style

Jayakumar, T.; Hsu, C.-Y.; Khamrang, T.; Hsia, C.-H.; Hsia, C.-W.; Manubolu, M.; Sheu, J.-R. Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy. Int. J. Mol. Sci. 2018, 19, 1818.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop